← Leaderboards
Laurie Sower
Chrysalis Biotherapeutics, Inc.
$8,454,436
Attributed
$8,454,436
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2M · FY2013–20$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$8,454,436 · 2
By mechanism
N01$6,954,509 · 1
N44$1,499,927 · 1
Top collaborators
No co-investigators on record.
Most similar at Chrysalis Biotherapeutics, Inc.
Same institution · by research overlap
- Darrell H. Carney$3,043,203
- Laurie E Sower$2,394,540
- Barbara Maria Olszewska-Pazdrak$648,663
Others in their field
Top investigators on “Prevent”
- Lawrence Corey · Fred Hutchinson Cancer Center$609,181,782
- Jeffrey P Krischer · University Of South Florida$605,511,231
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$530,065,238
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$499,311,118
- David Heimbrook · Leidos Biomedical Research, Inc.$496,394,926
Research focus
PreventRegenerativeClinical TrialsPeptidesDoseMetabolismIrradiationMusculoskeletalAnimalsExcretory FunctionInjuryBiological Response Modifier TherapyIschemiaLicensureFamily SuidaeDrug KineticsAlpha-ThrombinEmergency SituationDermalAnimal RuleCombatContractsAcuteAbsorption
Grant awards (5)
SUPPLEMENTAL WORK - SARS-COV-2 PRECLINICAL WORK$1,500,152
N01 · FY2020 · AI · contact PI
A NOVEL NUCLEAR COUNTERMEASURE TARGETING ENDOTHELIAL CELLS AND STEM CELLSTO COMBAT ARS AND DELAYED MULTIPLE ORGAN DYSFUNCTION$1,864,898
N01 · FY2019 · AI · contact PI
A NOVEL NUCLEAR COUNTERMEASURE TARGETING ENDOTHELIAL CELLS AND STEM CELLSTO COMBAT ARS AND DELAYED MULTIPLE ORGAN DYSFUNCTION$1,984,084
N01 · FY2018 · AI · contact PI
A NOVEL NUCLEAR COUNTERMEASURE TARGETING ENDOTHELIAL CELLS AND STEM CELLSTO COMBAT ARS AND DELAYED MULTIPLE ORGAN DYSFUNCTION$1,605,375
N01 · FY2017 · AI · contact PI
IGF::OT::IGF TP508 MITIGATES RADIOTHERAPY-INDUCED TISSUE DAMAGE - PERIOD OF PERF$1,499,927
N44 · FY2013 · CA · contact PI